13F Holdings
中文EN

AURX Nuo Therapeutics, Inc.

Surgical & Medical Instruments & Apparatus · OTC · SEC CIK 1091596 · Fiscal year ends 12/31

Financial factors as of 2025-09-30 (2025Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY123.7%
TTM net income YoY2.0%
TTM EPS YoY—
Revenue 3-yr CAGR308.7%
Net income 3-yr CAGR—

Margins

Gross margin70.4%
Operating margin-98.3%
Net margin-93.1%
FCF margin-44.6%
EBITDA margin-95.5%

Returns

ROE-1,032.5%
ROA-133.3%
ROIC (approx.)—
Asset turnover1.43x

Leverage & solvency

Liabilities / assets121.8%
Debt / equity—
Current ratio1.16x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.38x
Accruals ratio-82.1%
Payout ratio—
Capex / revenue8.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$3.31M$1.37M$608,525$112,250$0
Cost of revenue$1.10M$302,842$126,092$19,214$0
Gross profit$2.22M$1.06M$482,433$93,036$0
R&D expense————$0
SG&A expense$4.73M$3.52M$3.65M$3.41M$90,670
Operating income-$2.52M-$2.46M-$3.17M-$3.32M-$90,670
Interest expense————$0
Pretax income-$2.51M-$2.32M-$3.17M-$3.17M-$90,670
Income tax$0$0$0$0$0
Net income-$2.51M-$2.32M-$3.17M-$3.17M-$90,670
EBITDA-$2.43M-$2.43M-$3.15M-$3.31M-$90,670
EPS (basic)-0.05-0.05-0.08-0.08-0.03
EPS (diluted)————-0.03
Weighted avg. shares (diluted)————30.30M
Balance sheet
Cash & equivalents$548,946$283,714$928,681$2.05M$1.41M
Receivables$561,667$248,205$250,703$92,320$0
Inventory$213,761$150,442$209,589$240,005$0
Current assets$1.38M$841,546$1.56M$2.63M$1.47M
PP&E, net$366,315$177,022$45,082$53,165$0
Total assets$1.85M$1.19M$1.88M$3.05M$1.47M
Current liabilities$1.31M$578,451$674,527$600,431$673,079
Long-term debt————$0
Total debt————$0
Total liabilities$2.80M$675,796$838,732$856,022$673,079
Shareholders' equity-$956,559$513,712$1.04M$2.19M$792,839
Net debt————-$1.41M
Shares outstanding48.18M46.82M44.24M41.80M37.12M
Cash flow statement
Operating cash flow-$864,971-$2.23M-$3.17M-$3.71M-$119,955
Capital expenditure$274,756$154,962$7,244$59,992$0
Free cash flow-$1.14M-$2.39M-$3.18M-$3.77M-$119,955
Investing cash flow-$274,756-$154,962-$7,244-$59,992$0
Financing cash flow$1.40M$1.74M$2.00M$4.46M$1.37M
Depreciation & amortization$85,463$23,022$15,327$6,827$0
Stock-based compensation$85,986$56,652$21,746$9,145$13,936

Free plan shows the latest 5 periods; Pro shows all 15 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.